中等血管闭塞所致卒中的血管内治疗
ESCAPE-MeVO多中心前瞻性随机开放标签盲法终点试验纳入530例中等血管闭塞、发病12小时内且基线无创脑影像良好的急性缺血性卒中患者,比较血管内治疗联合常规治疗与单纯常规治疗。90天改良Rankin量表评分0或1分比例在血管内治疗组为41.6%,常规治疗组为43.1%(校正率比0.95,95%CI 0.79~1.15,P=0.61),无显著差异。90天死亡率血管内治疗组13.3%,常规治疗组8.4%(校正风险比1.82,95%CI 1.06~3.12)。症状性颅内出血血管内治疗组5.4%,常规治疗组2.2%。
要点
- 中等血管闭塞卒中12小时内血管内治疗90天良好预后(mRS 0~1)41.6% vs 常规治疗43.1%(校正率比0.95,95%CI 0.79~1.15,P=0.61),无显著差异。
- 血管内治疗组90天死亡率13.3% vs 常规治疗组8.4%(校正风险比1.82,95%CI 1.06~3.12)。
- 症状性颅内出血血管内治疗组5.4%(14/257) vs 常规治疗组2.2%(6/272)。
- 多数患者(84.7%)为大脑中动脉分支原发闭塞。
- 结论:中等血管闭塞急性缺血性卒中12小时内血管内治疗未带来优于常规治疗的90天预后。
适用人群与场景
- 急性缺血性卒中因中等血管闭塞,发病至最后已知良好时间12小时内,基线无创脑影像良好。
研究设计与关键结果
- 多中心、前瞻性、随机、开放标签、盲法终点评估试验,纳入5个国家530例患者,2022年4月至2024年6月入组,血管内治疗联合常规治疗组255例,单纯常规治疗组275例。
- 90天改良Rankin量表评分0或1分:血管内治疗组106/255(41.6%) vs 常规治疗组118/274(43.1%),校正率比0.95(95%CI 0.79~1.15,P=0.61)。
- 90天死亡率:血管内治疗组13.3% vs 常规治疗组8.4%,校正风险比1.82(95%CI 1.06~3.12)。
- 症状性颅内出血:血管内治疗组14/257(5.4%) vs 常规治疗组6/272(2.2%)。
- 84.7%患者原发闭塞位于大脑中动脉分支。
证据类型、等级与局限
- 证据类型:多中心前瞻性随机开放标签盲法终点试验(ESCAPE-MeVO,NCT05151172)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于中等血管闭塞所致急性缺血性卒中发病12小时内且基线无创脑影像良好者,血管内治疗未较常规治疗改善90天预后,作者认为该结果不支持在此类患者中常规开展血管内治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Whether the large effect size of endovascular thrombectomy (EVT) for stroke due to large-vessel occlusion applies to stroke due to medium-vessel occlusion is unclear.
METHODS: In a multicenter, prospective, randomized, open-label trial with blinded outcome evaluation, we assigned patients with acute ischemic stroke due to medium-vessel occlusion who presented within 12 hours from the time that they were last known to be well and who had favorable baseline noninvasive brain imaging to receive EVT plus usual care or usual care alone. The primary outcome was the modified Rankin scale score (range, 0 [no symptoms] to 6 [death]) at 90 days, reported as the percentage of patients with a score of 0 or 1.
RESULTS: A total of 530 patients from five countries were enrolled between April 2022 and June 2024, with 255 patients assigned to the EVT group and 275 to the usual-care group. Most patients (84.7%) had primary occlusions in a middle-cerebral-artery branch. A modified Rankin scale score of 0 or 1 at 90 days occurred in 106 of 255 patients (41.6%) in the EVT group and in 118 of 274 (43.1%) in the usual-care group (adjusted rate ratio, 0.95; 95% confidence interval [CI], 0.79 to 1.15; P = 0.61). Mortality at 90 days was 13.3% in the EVT group and 8.4% in the usual-care group (adjusted hazard ratio, 1.82; 95% CI, 1.06 to 3.12). Symptomatic intracranial hemorrhage occurred in 14 of 257 patients (5.4%) in the EVT group and in 6 of 272 (2.2%) in the usual-care group.
CONCLUSIONS: Endovascular treatment for acute ischemic stroke due to medium-vessel occlusion within 12 hours did not lead to better outcomes at 90 days than usual care. (Funded by the Canadian Institutes for Health Research and Medtronic; ESCAPE-MeVO ClinicalTrials.gov number, NCT05151172.).
参考来源
- Goyal M, Ospel JM, Ganesh A, et al. Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion. N Engl J Med. 2025. PMID: 39908448. doi:10.1056/NEJMoa2411668
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。